Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

This Drugmaker May Be On The Mend

Inside Wall Street


Investment manager Todd Krieg shook his head sadly as he looked at a stock chart showing the performance of Teva Pharmaceutical Industries (TEVIY). Teva is one of Israel's largest drugmakers and a worldwide producer of generic drugs. The stock, now at 57, is down from its June high of 67.

But Krieg isn't giving up. "We see in Teva what long-term investors want," says Krieg of First Star Capital in Milwaukee. He says Teva's world distribution network has helped earnings grow at a compounded 30% rate for the past 10 years.

Recently, Teva produced a proprietary drug called Copaxone that has not met expectations. But Krieg says the patented drug, a treatment for multiple sclerosis, will be a big winner in the long run. Over-optimistic projections for Copaxone, exacerbated by huge development costs, led to the disappointing results.

But with Copaxone's startup costs behind it, and with revenues coming on stream from eight generic products, Teva's stock is poised to rocket, say some pros. Teva trades on both the NASDAQ and Israeli stock exchanges. But the company sells 70% of its products overseas, mainly in the U.S. It makes antibiotics as well as anti-inflammatory and respiratory agents.

"We are bullish on Teva because it's in a better position to grow in a $265 billion generic market," says David Saks of Gruntal. He notes that Copaxone is on a "fast track, with 4,000 patients using it after just one quarter on the market." Saks has raised his 1997 earnings estimate to $2.42 a share (up from last year's $1.44), partly because of Copaxone's approval in Canada. The estimate excludes any payments from its marketing partner, Hoechst Marion Roussel, for approval in Europe.BY GENE G. MARCIALReturn to top

Return to top

blog comments powered by Disqus